Treatment of cutaneous angiosarcoma of the scalp and face in the Chinese patients: local experience at a regional hospital in Hong Kong

Chow, TL; Kwan, Wilson Wy; Kwan, CK

doi:10.12809/hkmj176813

Cited by 2 publications

(2 citation statements)

References 17 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings corroborate smaller studies that have similarly reported that S-XRT should be the standard of care when feasible to improve local control, disease-free survival, and disease-specific survival. 6,11,20,21 In addition to S-XRT, size ≥5 cm and multifocality at presentation were significantly associated with decreased LC, DSS, and OS. This was not surprising, as these factors have consistently been found to be poor prognostic variables in multiple prior studies.…”

Section: Discussionmentioning

confidence: 99%

Outcomes after definitive treatment for cutaneous angiosarcomas of the face and scalp: Reevaluating the role of surgery and radiation therapy

et al. 2023

View full text Add to dashboard Cite

Introduction We investigated outcomes and prognostic factors for patients treated for cutaneous angiosarcoma (CA). Methods We conducted a retrospective review of patients treated for CA of the face and scalp from 1962 to 2019. All received definitive treatment with surgery, radiation (RT), or a combination (S‐XRT). The Kaplan–Meier method was used to estimate outcomes. Multivariable analyses were conducted using the Cox proportional hazards model. Results For the 143 patients evaluated median follow‐up was 33 months. Five‐year LC was 51% and worse in patients with tumors >5 cm, multifocal tumors, those treated pre‐2000, and with single modality therapy (SMT). These remained associated with worse LC on multivariable analysis. The 5‐year disease‐specific survival (DSS) for the cohort was 56%. Tumor size >5 cm, non‐scalp primary site, treatment pre‐2000, and SMT were associated with worse DSS. Conclusion Large or multifocal tumors are negative prognostic factors in patients with head and neck CA. S‐XRT improved outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Outcomes after definitive treatment for cutaneous angiosarcomas of the face and scalp: Reevaluating the role of surgery and radiation therapy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Our current series further confirms the poor clinical outcomes for patients with a cutaneous angiosarcoma of the head, as previously reported in many studies. 4,5,8,13,15,20,21 Twelve patients only (40%) have survived following the cancer ablation process and continued on routine screening. Moreover, the majority of mortality in our series had occurred within two years of the diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Utility of Multimodal Treatment Protocols in the Management of Scalp Cutaneous Angiosarcoma

Alharbi‎

Kim

Alshomer

et al. 2023

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

Background: Cutaneous angiosarcomas are rare, aggressive tumors with high recurrence and poor prognosis. We share our experiences with the challenging surgical management of these lesions, focusing on both ablative and reconstructive outcomes. Methods: Retrospective cross-sectional chart review was conducted of patients diagnosed with scalp cutaneous angiosarcoma between 2005 and 2021. Resectability, defect reconstruction, and survival outcomes were analyzed. Results: Thirty patients were included, 27 (90%) men and three (10%) women, with a mean age at diagnosis of 71.77 ± 7.3 years, and mean follow-up of 429.43 ± 305.6 days. Only 12 patients completed their regular follow-up, while the remaining patients died. There was a median survival of 443.50 days (range, 42-1283) and median time to recurrence of 21 days (range, 30-1690). Multimodal therapy compared with surgery alone had a significantly better overall median survival (468 days versus 71 days; P = 0.021). Defect coverage was obtained in 24 cases (75%) through an anterolateral thigh flap, two patients (6%) with a local transposition flap, and one patient (3%) with a transverse rectus abdominis myocutaneous flap. The remaining three patients received a skin graft. All of the flaps survived, with one requiring a vein graft for venous congestion. Conclusions: Timely multimodal therapy with a histologically safe margin, combined with adjuvant therapy, improves survival and delays recurrence and metastasis, in cutaneous angiosarcoma patients. An anterolateral thigh flap facilitates the coverage of wide defects. Further investigations of advanced treatment modalities such as immunotherapy and/or gene therapy are required to deal with this highly aggressive tumor.

show abstract

Treatment of cutaneous angiosarcoma of the scalp and face in the Chinese patients: local experience at a regional hospital in Hong Kong

Cited by 2 publications

References 17 publications

Outcomes after definitive treatment for cutaneous angiosarcomas of the face and scalp: Reevaluating the role of surgery and radiation therapy

Outcomes after definitive treatment for cutaneous angiosarcomas of the face and scalp: Reevaluating the role of surgery and radiation therapy

Utility of Multimodal Treatment Protocols in the Management of Scalp Cutaneous Angiosarcoma

Contact Info

Product

Resources

About